![]() ![]() The Proxima CRO EPON includes a network of Phase I cancer research clinics and investigators serving patients who need innovative treatments for their advanced cancers. Headquartered in the Texas Medical Center Innovation Center at the heart of healthcare and life sciences innovation, Proxima CRO has a vast network of cancer research clinics in the United States. This new relationship with Proxima CRO's EPON will help us further enhance our mission and contribute to our life's work of advancing cancer treatments to save more lives from cancer around the world." "We proudly designed NEXT Oncology specifically to bring the best new agents to patients through our specially designed centers located around the world. "Early phase oncology trials are some of the most delicate and important trials to conduct, both from a science perspective and in offering hope for late-stage patients," says Anthony (Tony) Tolcher, MD, FRCPC, FACP, CEO & Founder of NEXT Oncology. For people with advanced cancers whose current therapy is no longer providing benefit, we get excited that we can offer access to the newest treatments available to give them a fighting chance." ![]() "Proxima's EPON further empowers us to continue our mission of transforming the industry through the development of the next breakthrough in cancer research with high-quality Phase I clinical pharmacology trials. "Proxima CRO's EPON allows our early phase investigators across NEXT Oncology to continue the advancement of cancer research to further bridge the gap between patient needs and effective cancer treatments," says Alex Spira, MD, PhD, FACP, clinical director and CEO of NEXT Oncology Virginia. An early adopter within the Proxima CRO EPON, the research sites work collaboratively to advance and provide breakthroughs in cancer research. Serving patients out of Virginia, Austin, Dallas, San Antonio, and abroad in Barcelona and Madrid, NEXT Oncology offers access to new investigational therapies through the administration of Phase I clinical trials. NEXT Oncology is a Phase I clinical trial treatment center dedicated to the advancement of early-phase cancer research through clinical trials of anticancer agents with the goal of providing innovative developments in cancer treatment. With six locations conducting early-phase clinical trials, NEXT Oncology is the latest group to join Proxima CRO's vast network of clinical research centers located throughout the United States. With some of the most prominent early phase clinical trial investigators working at NEXT Oncology, we look forward to advancing opportunities for breakthroughs in cancer development in these earliest phase trials." NEXT Oncology and Proxima Clinical Research team up to further advance patient access to new investigational therapies that could save lives and advance the field of cancer care. "Adding NEXT Oncology to our Early Phase Oncology Network is a huge step towards incorporating early scientific and operational feedback, insight, and guidance into the development and execution of Phase I clinical trials. ![]() "We specialize in bringing next-generation therapies from concept to patients as quickly as possible to give patients a fighting chance and investigators vital information to continue to advance treatments at an accelerated rate," says Robbin Frnka, Executive Director of Clinical Development and Strategy at Proxima CRO. HOUSTON, TX / ACCESSWIRE / J/ Proxima Clinical Research ("Proxima CRO"), a contract research organization ("CRO") located in the heart of innovation in Houston, announced today it is expanding its Early Phase Oncology Network ("EPON") with the addition of NEXT Oncology, a Phase I clinical trial treatment center dedicated to providing patients with advanced cancer with access to the newest cancer treatments available. The addition of NEXT Oncology investigators expands Proxima CRO's Phase I clinical trials offering with expert insight ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |